UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 651

Sortiert nach

Accretion of the Earth and segregation of its core

Nature, 2006-06, Vol.441 (7095), p.825-833

2006

Link zum Volltext

Verfügbarkeit prüfen

Late Accretion on the Earliest Planetesimals Revealed by the Highly Siderophile Elements

Science (American Association for the Advancement of Science), 2012-04, Vol.336 (6077), p.72-75

2012

Link zum Volltext

Verfügbarkeit prüfen

Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9514-9514

2020

Link zum Volltext

Verfügbarkeit prüfen

An assessment of powder pycnometry as a means of determining granule porosity

Pharmaceutical development and technology, 2015-05, Vol.20 (3), p.257-265

2015

Link zum Volltext

Verfügbarkeit prüfen

Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3004-3004

2017

Link zum Volltext

Verfügbarkeit prüfen

CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3001-3001

2016

Link zum Volltext

Verfügbarkeit prüfen

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8010-8010

2014

Link zum Volltext

Verfügbarkeit prüfen

First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.2524-2524

2013

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 study of an off-the shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2616-2616

2021

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA

Journal of clinical oncology, 2020-06, Vol.38 (18_suppl), p.LBA5-LBA5

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21682-e21682

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib/II study of niraparib plus temozolomide plus atezolizumab versus atezolizumab as maintenance therapy in extensive-stage small cell lung cancer (TRIO-US L-06)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS9084-TPS9084

2020

Link zum Volltext

Verfügbarkeit prüfen

Neratinib efficacy in a subgroup of patients with EGFR exon 18 - mutant non-small cell lung cancer (NSCLC) and central nervous system (CNS) involvement: Findings from the SUMMIT basket trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9068-9068

2021

Link zum Volltext

Verfügbarkeit prüfen

The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9059-9059

2021

Link zum Volltext

Verfügbarkeit prüfen

EGFR-mutation detection in VTX-1-enriched CTCs, ctDNA, and comparison to tumor in patients with non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e20525-e20525

2017

Link zum Volltext

Verfügbarkeit prüfen

c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9023-9023

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3003-3003

2020

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumor DNA (ctDNA) mutations may predict treatment response in extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib and temozolomide (TMZ)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8564-8564

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of in situ vaccination with autologous CCL21 -modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS9135-TPS9135

2021

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab (nivo) + nab -paclitaxel ( nab -P) + carboplatin (C) in patients (pts) with non-small cell lung cancer (NSCLC): Interim results from a multicenter phase I study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.9095-9095

2017

Link zum Volltext

Verfügbarkeit prüfen

Clinical implications of the T790M mutation in disease characteristics and treatment response in patients with EGFR-mutated NSCLC

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.9031-9031

2017

Link zum Volltext

Verfügbarkeit prüfen

Tuning interfacial interactions for bottom‐up assembly of surface‐anchored metal‐organic frameworks to tailor film morphology and pattern surface features: Nanoscience: Special Issue Dedicated to Professor Paul S. Weiss

Aggregate (Hoboken), 2022-08, Vol.3 (4)

2022

Link zum Volltext

Verfügbarkeit prüfen

Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3011-3011

2020

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9002-9002

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 651

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

KollektionProject MUSE All Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(575)
Mit Volltextzugriff
(565)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(396)
Life Sciences & Biomedicine
(320)
Humans
(259)
Male
(126)
Female
(123)
Adult
(83)
Middle Aged
(79)
Aged
(66)
General & Internal Medicine
(55)
Patients
(46)
Neurosciences & Neurology
(42)
Science & Technology - Other Topics
(41)
Animals
(39)
Biological And Medical Sciences
(39)
Multidisciplinary Sciences
(39)
Medicine, General & Internal
(36)
Surgery
(35)
Oncology
(34)
Clinical Trials
(33)
Physical Sciences
(33)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Accretion of the Earth and segregation of its core

Late Accretion on the Earliest Planetesimals Revealed by the Highly Siderophile Elements

Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients

An assessment of powder pycnometry as a means of determining granule porosity

Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients

CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)

First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M

A phase 1 study of an off-the shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA

A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC)

A phase Ib/II study of niraparib plus temozolomide plus atezolizumab versus atezolizumab as maintenance therapy in extensive-stage small cell lung cancer (TRIO-US L-06)

Neratinib efficacy in a subgroup of patients with EGFR exon 18 - mutant non-small cell lung cancer (NSCLC) and central nervous system (CNS) involvement: Findings from the SUMMIT basket trial

The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study

EGFR-mutation detection in VTX-1-enriched CTCs, ctDNA, and comparison to tumor in patients with non-small cell lung cancer (NSCLC)

c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors

Circulating tumor DNA (ctDNA) mutations may predict treatment response in extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib and temozolomide (TMZ)

Phase I trial of in situ vaccination with autologous CCL21 -modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC

Nivolumab (nivo) + nab -paclitaxel ( nab -P) + carboplatin (C) in patients (pts) with non-small cell lung cancer (NSCLC): Interim results from a multicenter phase I study

Clinical implications of the T790M mutation in disease characteristics and treatment response in patients with EGFR-mutated NSCLC

Tuning interfacial interactions for bottom‐up assembly of surface‐anchored metal‐organic frameworks to tailor film morphology and pattern surface features: Nanoscience: Special Issue Dedicated to Professor Paul S. Weiss

Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study

Aktive Filter

Suchergebnisse filtern